Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...

Sionna Therapeutics SION) stock rises as the clinical-stage biopharma focused on cystic fibrosis therapies makes its public ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...

Sionna Therapeutics, Inc SION IPO will take place February, 07 on the NASDAQ exchange under the ticker SION. The company is ...

Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

Lennox Hodgkinson of Nova Scotia was dressed all in Blackhawks gear for what his dad described as ...

A Nova Scotia native and Blackhawks fan, Lennox was diagnosed with cystic fibrosis when he was three weeks old. While he undergoes daily treatments, medications and deals with frequent sickness, ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.